Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.45 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.45 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | HCK | P08631 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | CDK8 | P49336 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18853884 | 0.88 | FYN (0.46) | CLK4CSNK1G2KDRABL1EGFR | |
| SCHEMBL14555416 | 0.82 | MEN1 (0.46) | MAP4K4CLK4CSNK1G2MKNK2MAP4K5 | |
| SCHEMBL20466856 | 0.76 | NCOA1 (0.42) | CLK4EIF4E | |
| SCHEMBL15724380 | 0.76 | CYP17A1 (0.46) | CLK4ACVR1JAK2 | |
| SCHEMBL20371563 | 0.75 | PIK3CD (0.46) | KDRABL1PIK3CDEGFRHCK | |
| SCHEMBL17742694 | 0.75 | MKNK2 (0.55) | MAP4K4CLK4CSNK1G2MKNK2MAP4K5 | |
| SCHEMBL26356060 | 0.74 | AKR1C3 (0.47) | MAP4K4CLK4CSNK1G2MKNK2MAP4K5 | |
| SCHEMBL15723936 | 0.73 | KDM4E (0.63) | ABL1PIK3CDSRCPIK3CAPIK3CB | |
| SCHEMBL2456422 | 0.72 | S100A4 (0.55) | MAP4K4CLK4CSNK1G2MKNK2MAP4K5 | |
| SCHEMBL1449798 | 0.71 | MAPT (0.53) | MAP4K4CLK4CSNK1G2MKNK2MAP4K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | MAP4K4 1858/4885CLK4 4388/4885CSNK1G2 2320/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MAP4K4 1858/4885CLK4 4388/4885CSNK1G2 2320/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MAP4K4 1858/4885CLK4 4388/4885CSNK1G2 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.